Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 Apr 10:1:9.
doi: 10.1186/1748-717X-1-9.

Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study

U Ganswindt  1 , W Budach, V Jendrossek, G Becker, M Bamberg, C Belka
Affiliations
Clinical Trial

Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study

U Ganswindt et al. Radiat Oncol. .

Abstract

Background: Current approaches for the improvement of bNED for prostate cancer patients treated with radiotherapy mainly focus on dose escalation. However molecularly targeted approaches may also turn out to be of value. In this regard cyclooxygenase (COX)-2 inhibitors have been shown to exert some anti-tumour activities in human prostate cancer in vivo and in vitro. Although in vitro data indicated that the combination of COX-2 inhibition and radiation was not associated with an increased toxicity, we performed a phase I trial using high dose celecoxib together with percutaneous radiation therapy.

Methods: In order to rule out any increases of more than 20% incidence for a given side effect level 22 patients were included in the trial. Celecoxib was given 400 mg twice daily with onset of the radiation treatment. Risk adapted radiation doses were between 70 and 74 Gy standard fractionation. RTOG based gastrointestinal (GI) and genitourinary (GU) acute toxicity scoring was performed weekly during radiation therapy, at six weeks after therapy and three month after completing radiation treatment.

Results: Generally no major increase in the level and incidence of side effects potentially caused by the combined treatment was observed. In two cases a generalised skin rash occurred which immediately resolved upon discontinuation of the drug. No grade 3 and 4 toxicity was seen. Maximal GI toxicity grade 1 and 2 was observed in 85% and 10%, respectively. In terms of GU toxicity 80% of the patients experienced a grade 1 toxicity and 10 % had grade 2 symptoms.

Conclusion: The combination of irradiation to the prostate with concurrent high dose celecoxib was not associated with an increased level of side effects.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Acute gastrointestinal toxicity (RTOG).
Figure 2
Figure 2
Acute genitourinary toxicity (RTOG).
Figure 3
Figure 3
Acute skin toxicity (RTOG).
Figure 4
Figure 4
Dose-volume-histograms of the rectum.
See this image and copyright information in PMC

References

    1. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 2000;92:1582–1592. doi: 10.1093/jnci/92.19.1582. - DOI - PubMed
    1. Fiveash JB, Hanks G, Roach M, Wang S, Vigneault E, McLaughlin PW, Sandler HM. 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review. Int J Radiat Oncol Biol Phys. 2000;47:335–342. doi: 10.1016/S0360-3016(00)00441-7. - DOI - PubMed
    1. Valicenti R, Lu J, Pilepich M, Asbell S, Grignon D. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol. 2000;18:2740–2746. - PubMed
    1. Kupelian PA, Buchsbaum JC, Reddy CA, Klein EA. Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10) Int J Radiat Oncol Biol Phys. 2001;50:621–625. doi: 10.1016/S0360-3016(01)01466-3. - DOI - PubMed
    1. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166:876–881. doi: 10.1016/S0022-5347(05)65855-7. - DOI - PubMed

Publication types